Peptide-coupled alginate gels comprising radionuclides
AssigneeBlue Wave Therapeutics GmbH
InventorsMichael DORNISH, Jostein DAHLE
Life of this patent
Estimating the term…
Abstract
The present invention relates to alginate-based gels for use in radiotherapy. More particularly, the invention provides an alginate gel comprising a peptide-coupled alginate, at least one type of divalent cation, and at least one radionuclide cation; a method for providing at least one alginate gel particle; a composition comprising said alginate gel; said alginate gel or composition for use as a medicament; said alginate gel or composition for use in a method for the treatment of a proliferative disease; and kits comprising an alginate and a radionuclide cation.
Claims20
An alginate gel comprising
- an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease;
- at least one type of divalent cations selected from the group comprising Ba2+, Sr2+, Ca2+, Cu2+, Zn2+, and combinations thereof;
- and
- at least one radionuclide cation selected from the group comprising actinium-225, actinium-228, astatine-211, barium-140, bismuth-210, bismuth-211, bismuth-212, bismuth-213, calcium-45, calcium-47, copper-64, francium-221, gallium-67, holmium-166, indium-111, iridium-192, iron-59, lead-211, lead-212, lead-214, lutetium-177, osmium-191, osmium-193, palladium-103, platinum-197, radium-223, radium-224, radium-225, rhenium-186, rhenium-188, samarium-153, scandium-46, scandium-47, silver-111, strontium-85, strontium-89, tellurium-129, tellurium-132, terbium-160, terbium-161, thallium-201, thallium-206, thallium-210, thorium-227, thorium-231, thorium-234, tin-113, tungsten-185, tungsten-187, vanadium-48, ytterbium-169, yttrium-88, yttrium-90, yttrium-91, zirconium-95, and combinations thereof,
- wherein the alginate chelates the divalent cations and the at least one radionuclide cation.
A method for providing at least one alginate gel particle comprising an alginate comprising at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease and at least one radionuclide cation, wherein the method comprises the steps of
- i) providing a solution of an alginate, wherein the alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease;
- ii) dripping the solution from step i) into an aqueous solution comprising a divalent cation, wherein said divalent cation is selected from Ca2+, Sr2+, and Ba2+, to form at least one alginate gel particle;
- and
- iii) contacting the alginate gel particle of step ii) with a solution comprising at least one radionuclide cation.
A kit comprising,
- in a first container,
- an alginate gel comprising
- an alginate comprising
- at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease;
- and
- at least one type of divalent cations selected from the group comprising Ba2+, Sr2+, Ca2+, Cu2+, Zn2+, and combinations thereof;
- and
- optionally, a suitable solvent;
- and
- in a second container,
- at least one radionuclide cation, and
- a suitable solvent.
A kit comprising,
- in a first container,
- a water-soluble alginate,
- wherein the alginate comprises at least one peptide having a peptide sequence for interacting with a receptor of a cell affected by a proliferative disease,
- water, and
- optionally, another suitable solvent;
- in a second container,
- particles that are insoluble in water, said particles comprising an alginate and at least one type of divalent cation selected from the group comprising Ba2+, Sr2+, Ca2+, Cu2+, Zn2+, and combinations thereof, and
- water;
- and
- in a third container
- at least one radionuclide cation, and
- a suitable solvent.
(canceled)
Dependencies are inferred from the claim text.